AU2001296001A1 - Process for producing b-form nateglinide crystal - Google Patents

Process for producing b-form nateglinide crystal

Info

Publication number
AU2001296001A1
AU2001296001A1 AU2001296001A AU9600101A AU2001296001A1 AU 2001296001 A1 AU2001296001 A1 AU 2001296001A1 AU 2001296001 A AU2001296001 A AU 2001296001A AU 9600101 A AU9600101 A AU 9600101A AU 2001296001 A1 AU2001296001 A1 AU 2001296001A1
Authority
AU
Australia
Prior art keywords
producing
nateglinide
type crystals
crystals
nateglinide crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001296001A
Other languages
English (en)
Inventor
Makoto Maruo
Yukiko Matsuzawa
Kazuo Miyazaki
Shigehiro Nishina
Michito Sumikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of AU2001296001A1 publication Critical patent/AU2001296001A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C07C227/42—Crystallisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001296001A 2000-10-24 2001-10-23 Process for producing b-form nateglinide crystal Abandoned AU2001296001A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-324375 2000-10-24
JP2000324375 2000-10-24
PCT/JP2001/009293 WO2002034713A1 (fr) 2000-10-24 2001-10-23 Procede de production de cristaux de nateglinide a forme b

Publications (1)

Publication Number Publication Date
AU2001296001A1 true AU2001296001A1 (en) 2002-05-06

Family

ID=18801920

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001296001A Abandoned AU2001296001A1 (en) 2000-10-24 2001-10-23 Process for producing b-form nateglinide crystal

Country Status (18)

Country Link
US (2) US20030229249A1 (enrdf_load_stackoverflow)
EP (1) EP1334964B1 (enrdf_load_stackoverflow)
JP (1) JP4225057B2 (enrdf_load_stackoverflow)
KR (1) KR100810930B1 (enrdf_load_stackoverflow)
CN (1) CN100422143C (enrdf_load_stackoverflow)
AT (1) ATE370115T1 (enrdf_load_stackoverflow)
AU (1) AU2001296001A1 (enrdf_load_stackoverflow)
BR (1) BR0114846A (enrdf_load_stackoverflow)
CA (1) CA2426745C (enrdf_load_stackoverflow)
CY (1) CY1106839T1 (enrdf_load_stackoverflow)
DE (1) DE60130014T2 (enrdf_load_stackoverflow)
DK (1) DK1334964T3 (enrdf_load_stackoverflow)
ES (1) ES2288997T3 (enrdf_load_stackoverflow)
MX (1) MXPA03003575A (enrdf_load_stackoverflow)
PT (1) PT1334964E (enrdf_load_stackoverflow)
RU (1) RU2275354C2 (enrdf_load_stackoverflow)
TW (1) TWI293290B (enrdf_load_stackoverflow)
WO (1) WO2002034713A1 (enrdf_load_stackoverflow)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070104953A (ko) * 2000-03-17 2007-10-29 아지노모토 가부시키가이샤 신경 장애용 약제
CA2425538C (en) * 2000-10-18 2010-10-12 Ajinomoto Co., Inc. Methods for producing nateglinide crystals
ATE373635T1 (de) * 2000-10-18 2007-10-15 Ajinomoto Kk Verfahren zur herstellung von acylphenylalaninen
CN100352432C (zh) * 2000-10-24 2007-12-05 味之素株式会社 含有那格列奈的制剂
CA2426764C (en) * 2000-10-24 2010-04-20 Ajinomoto Co., Inc. Nateglinide-containing hydrophilic pharmaceutical preparation
US7411089B2 (en) 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals
EP1496048A4 (en) * 2002-04-15 2006-08-02 Ajinomoto Kk NEW NATEGLINID CRYSTAL
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
US7420084B2 (en) 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7148376B2 (en) 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7358390B2 (en) 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
IL166308A0 (en) * 2002-07-18 2006-01-15 Polymorphic forms of nateglinide
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
DE60310734T2 (de) * 2003-11-26 2007-10-11 A.M.S.A. Anonima Matèrie Sintètiche e Affini S.p.A. Verfahren zur Herstellung von Nateglinid in der B-Form
CA2563793A1 (en) * 2004-05-07 2005-11-24 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
WO2005110395A1 (en) * 2004-05-19 2005-11-24 University Of South Carolina System and device for magnetic drug targeting with magnetic drug carrier particles
US20080096970A1 (en) * 2004-05-20 2008-04-24 Sundaram Venkataraman Stable Nateglinide Form B Compositions
US7425648B2 (en) 2005-01-03 2008-09-16 A.M.S.A. Anonima Materie Sintetiche E. Affini S.P.A. Process for the preparation of nateglinide, preferably in B-form
KR20070102694A (ko) * 2005-01-31 2007-10-19 아지노모토 가부시키가이샤 혈당 강하제를 함유하는, 내당능 이상, 경계형 당뇨병,인슐린 저항성 및 고인슐린혈증 개선 또는 치료용 의약조성물
WO2007135533A1 (en) * 2006-05-23 2007-11-29 Aurobindo Pharma Limited Process for preparing nateglinide b-type crystals
KR100837843B1 (ko) * 2006-12-26 2008-06-13 씨제이제일제당 (주) 나테글리나이드 결정형, 그 제조방법, 및 그를 포함하는약제학적 조성물
KR20130087485A (ko) 2010-06-14 2013-08-06 씨아이피엘에이 엘티디. 나테글리니드의 제조 방법
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
SG11201407300VA (en) 2012-05-07 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of neurological disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
CN104364230A (zh) * 2012-05-08 2015-02-18 塞利克斯比奥私人有限公司 用于治疗糖尿病的组合物和方法
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
US9403857B2 (en) 2012-05-10 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9498461B2 (en) 2012-05-23 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
JP2015518854A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 多発性硬化症の治療のための組成物および方法
US9765020B2 (en) 2012-05-23 2017-09-19 Cellix Bio Private Limited Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
CN104364231A (zh) 2012-09-08 2015-02-18 塞利克斯比奥私人有限公司 用于治疗炎症和脂质异常的组合物和方法
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
NZ736131A (en) 2014-09-26 2019-04-26 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
JP6698643B2 (ja) 2014-09-29 2020-05-27 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための組成物及び方法
WO2016098119A1 (en) 2014-10-27 2016-06-23 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
CN104402756B (zh) * 2014-11-27 2016-08-31 天方药业有限公司 一种高纯度那格列奈的制备方法
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
JP6679616B2 (ja) 2015-01-06 2020-04-22 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 炎症及び疼痛の治療のための組成物及び方法
CN109369443A (zh) * 2018-11-05 2019-02-22 扬子江药业集团江苏海慈生物药业有限公司 一种新的那格列奈h晶型的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6354321A (ja) * 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
AU615966B2 (en) * 1987-12-04 1991-10-17 Takeda Chemical Industries Ltd. Crystals of cephem hydrochloride
US5463116A (en) * 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
DE69217762T2 (de) * 1991-07-30 1997-10-09 Ajinomoto Kk Kristalle von N-(Trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung
TW492878B (en) * 1996-11-15 2002-07-01 Ajinomoto Kk Tablet composition
US6844006B1 (en) * 1999-07-09 2005-01-18 Pennfield Oil Company Process and apparatus for the preparation of chlortetracycline-containing animal feed compositions
ATE399000T1 (de) * 1999-12-28 2008-07-15 Ajinomoto Kk Antidiabetes-zubereitung zur oralen verabreichung
KR20070104953A (ko) * 2000-03-17 2007-10-29 아지노모토 가부시키가이샤 신경 장애용 약제
CA2425538C (en) * 2000-10-18 2010-10-12 Ajinomoto Co., Inc. Methods for producing nateglinide crystals
ATE373635T1 (de) * 2000-10-18 2007-10-15 Ajinomoto Kk Verfahren zur herstellung von acylphenylalaninen
CN100352432C (zh) * 2000-10-24 2007-12-05 味之素株式会社 含有那格列奈的制剂
US7411089B2 (en) * 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals

Also Published As

Publication number Publication date
TWI293290B (enrdf_load_stackoverflow) 2008-02-11
RU2275354C2 (ru) 2006-04-27
CY1106839T1 (el) 2012-05-23
DK1334964T3 (da) 2007-09-24
CA2426745A1 (en) 2003-04-23
KR20030059212A (ko) 2003-07-07
US7544834B2 (en) 2009-06-09
BR0114846A (pt) 2004-02-25
ATE370115T1 (de) 2007-09-15
PT1334964E (pt) 2007-09-20
CN100422143C (zh) 2008-10-01
DE60130014T2 (de) 2008-05-08
KR100810930B1 (ko) 2008-03-10
US20070232829A1 (en) 2007-10-04
EP1334964A4 (en) 2005-09-28
DE60130014D1 (de) 2007-09-27
JP4225057B2 (ja) 2009-02-18
ES2288997T3 (es) 2008-02-01
CN1483018A (zh) 2004-03-17
WO2002034713A1 (fr) 2002-05-02
US20030229249A1 (en) 2003-12-11
EP1334964A1 (en) 2003-08-13
MXPA03003575A (es) 2003-07-14
JPWO2002034713A1 (ja) 2004-03-04
EP1334964B1 (en) 2007-08-15
CA2426745C (en) 2009-09-15

Similar Documents

Publication Publication Date Title
AU2001296001A1 (en) Process for producing b-form nateglinide crystal
RU2003111948A (ru) Способы получения кристаллов в-типа натеглинида
PL365613A1 (en) Crystalline and pure modafinil, and process of preparing the same
KR910009563A (ko) 고순도 실리카의 제조방법
CA2248143A1 (en) Process to prepare oxazolidinones
PL357860A1 (en) Interketaled graphite compounds capable to expand, method of obtaining them and their applications
CA2301863A1 (en) Polymorphs modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same
EP1681263A4 (en) PROCESS FOR CLEANING LITHIUM SULFIDE
RU2002104026A (ru) Ингибиторы сериновых протеаз
AU2001253376A1 (en) Improved process for the conversion of an aqueous biomass hydrolyzate into fuelsor chemicals by the selective removal of fermentation inhibitors
DE50305423D1 (de) Mutter und verfahren zu ihrer herstellung
EP1318201A4 (en) PROCESS FOR PRODUCING PURIFIED ANTHOCYANIN AND CRYSTALLINE ANTHOCYANIN
CA2326441A1 (en) Process for purification of a cephalosporin derivative
CA2234650A1 (en) Method for producing calcium borate
DE60235318D1 (de) Dikarbonsäuresalze des acetyl-l-carnitins und verfahren zu ihrer herstellung
DK1095009T3 (da) Fremgangsmåde til fremstilling af 4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-carboxylsyre
AU2321900A (en) Process for the preparation of alpha-aminoketones
IL145723A0 (en) Process for producing an amide compound
EP1431278A4 (en) METHOD FOR PRODUCING (2-NITROPHENYL) ACETONITRILE DERIVATIVES AND ASSOCIATED INTERMEDIATES
WO2003057665A1 (fr) Procede de production d'un cristal d'un derive de benzenesulfonamide, et nouveau cristal d'un produit intermediaire de ce derive et son procede de production
DE60023232D1 (de) Kristallisierung von Alpha-L-Aspartyl-L-Phenylalaninmethylester aus übersättigten Lösungen
WO2003087118A3 (de) Verfahren zur herstellung von beta-l-2'deoxy-thymidin
PT994119E (pt) Processo estereosselectivo para a preparacao do epimero 22r de budesonide
ATE423215T1 (de) Verfahren zur herstellung von lysosphingolipiden
EP0895980A4 (en) 3-HYDROXYMETHYLCYCLOALCANOLS AND THEIR PRODUCTION PROCESS